CARLSBAD, Calif.--(BUSINESS WIRE)--Regulus Therapeutics Inc. today announced that new data from its metabolic disease program were presented at the “Diabetes” Keystone Symposium held April 12-17 in Whistler, British Columbia. The new pre-clinical research findings showed that therapeutic oligonucleotides targeting microRNA are able to improve insulin resistance and normalize plasma glucose in mouse models of diabetes while having no significant effect on glucose or insulin levels in normal mice. The increased incidence of diabetes is a growing threat to global health, and microRNA therapeutics represent a promising strategy for the discovery and development of novel anti-diabetic agents.
